Literature DB >> 8170836

TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin.

P Russo1, J A Warner, R Huryk, G Perez, W D Heston.   

Abstract

TRPM-2, not normally expressed in the rat ventral prostate, has been identified as an important genetic marker of castration-induced apoptotic cell death. It is not known whether other agents capable of causing growth inhibition of the rat ventral prostate also induce TRPM-2 expression. To investigate this further, 270 mature Sprague-Dawley rats were randomized into one of six groups: control, castration, diethylstilbestrol (DES), flutamide, MK-906 (finasteride), or coumarin. Five rats per group were sacrificed on days 1, 3, 5, 7, 10, and 21. Serum testosterone, body weights, and prostate weights were determined at each time point. The ventral prostate was removed and cellular RNA extracted. Northern blot analysis using cDNA probes for TRPM-2 and gamma-actin were performed at each time point. Only DES significantly decreased rat weights. DES and castration reduced serum testosterone to undetectable levels by the next day. Flutamide caused a 3.0- to 4.5-fold increase in serum testosterone above control. Coumarin and MK-906 did not affect serum testosterone levels. DES and castration reduced prostate weights to 20% and 6% of control, respectively, while inducing TRPM-2 expression to a maximum on day 5 of the experiment. DES induced TRPM-2 expression over a longer duration than did castration, suggesting that more than just the decrease of serum testosterone to castrate levels plays a role in the expression of TRPM-2. MK-906, coumarin, and flutamide reduced prostatic weights to a lesser extent (50%, 63%, 71% of control, respectively), but these agents did not induce TRPM-2 expression at any time during the experiment. TRPM-2 expression in the rat ventral prostate does not correlate simply with catabolic effects on the prostate.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8170836     DOI: 10.1002/pros.2990240504

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

1.  Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.

Authors:  R Montironi; M Valli; G Fabris
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

2.  Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death.

Authors:  C R Yang; K Leskov; K Hosley-Eberlein; T Criswell; J J Pink; T J Kinsella; D A Boothman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat.

Authors:  A S Wright; L N Thomas; R C Douglas; C B Lazier; R S Rittmaster
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

4.  Changes in gene expression following androgen receptor blockade is not equivalent to androgen ablation by castration in the rat ventral prostate.

Authors:  Anil M Limaye; Irfan Asangani; Thyagarajan Kalyani; Paturu Kondaiah
Journal:  J Biosci       Date:  2008-06       Impact factor: 1.826

5.  Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat.

Authors:  S M Ho; I Leav; S Ghatak; F Merk; V S Jagannathan; K Mallery
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.